|
09 Feb 2025
|
Akums Drugs & Pharma
|
ICICI Securities Limited
|
510.25
|
710.00
|
560.90
(-9.03%)
|
39.15 |
Buy
|
|
|
Akums Drugs and Pharmaceuticals (Akums) in Q3FY25 saw its CDMO business’ volumes recovering (+0.6% YoY). Growth in CDMO should pick up in the next few quarters given Akums’ healthy order book alongside API prices also settling.
|
|
30 Jul 2024
|
Akums Drugs & Pharma
|
SBI Securities
|
510.25
|
|
|
|
IPO Subscribe
|
|
|
|
|
29 Jul 2024
|
Akums Drugs & Pharma
|
HDFC Securities
|
510.25
|
|
|
|
IPO Note
|
|
|
Akums Drugs and Pharmaceuticals Limited - IPO Note Issue Snapshot: Issue Open: July 30 August 01, 2024 Price Band: Rs. 646 679 (Discount of Rs 64 per share for all eligible employees) *Issue Size: Up to Rs 1856.7 cr (including Fresh issue of Rs 680 cr + Offer for sale of 17,330,435 eq share including employee reservation of upto Rs.15 cr Reservation for: QIB atleast 75% eq sh Non-Institutional upto 15% eq sh ((including 1/3rd for applications between Rs.2 lakhs to Rs.10 lakhs)) Retail upto 10% eq sh Face Value: Rs 2 Book value: Rs 49.59 (March 31, 2024) Bid size: - 22 equity shares and in multiples thereof 100% Book built Issue
|
|
29 Jul 2024
|
Akums Drugs & Pharma
|
KRChoksey
|
510.25
|
|
|
|
IPO Subscribe
|
|
|
Akums Drugs and Pharmaceuticals established in 2004 offers a comprehensive range of pharmaceutical products and services to cater to the diverse needs of its clients in India and abroad. Through its core CDMO business, it provides end-to-end solutions for product development and manufacturing.
|
|
29 Jul 2024
|
Akums Drugs & Pharma
|
Ashika Research
|
510.25
|
|
|
|
IPO Note
|
|
|
|
|
29 Jul 2024
|
Akums Drugs & Pharma
|
Ventura
|
510.25
|
|
|
|
IPO Subscribe
|
|
|
|
|
29 Jul 2024
|
Akums Drugs & Pharma
|
Hem Securities
|
510.25
|
|
|
|
IPO Subscribe
|
|
|
|
|
29 Jul 2024
|
Akums Drugs & Pharma
|
IDBI Capital
|
510.25
|
|
|
|
IPO Subscribe
|
|
|
|